Roopashree Prabhushankar, MD
Endocrinology, Diabetes & Metabolism · Mesa, AZNPI 1831402429
Payments from drug & device makers
Across 114 payments — averaging $26.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$679
- Corcept Therapeutics$419
- Boehringer Ingelheim$354
- Mannkind Corporation$257
- Xeris Pharmaceuticals, Inc.$159
- Abbott$159
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,87594%
- Education$612%
- Gifts$1194%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $679 |
| Corcept Therapeutics | 6 | $419 |
| Boehringer Ingelheim | 19 | $354 |
| Mannkind Corporation | 14 | $257 |
| Xeris Pharmaceuticals, Inc. | 9 | $159 |
| Abbott | 5 | $159 |
| Dexcom, Inc. | 7 | $152 |
| Madrigal Pharmaceuticals | 1 | $128 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Novo Nordisk | 2 | $111 |
| Lilly USA, LLC | 6 | $106 |
| Sanofi-aventis U.S. LLC | 3 | $63 |
| Shire North American Group Inc | 3 | $43 |
| OPKO Pharmaceuticals, LLC | 2 | $42 |
| Recordati_rare_diseases_inc. | 2 | $41 |
| Pfizer | 2 | $39 |
| Currax Pharmaceuticals LLC | 2 | $39 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Calliditas Therapeutics US Inc. | 1 | $18 |
| Amgen | 1 | $16 |
| Medtronic | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Strongbridge US Inc. | 1 | $14 |
| Cequr Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,055 in reported general payments places this provider in the 45th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 316 | $500,518 |
| JardianceEmpagliflozin | 120 | $149,712 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 83 | $138,118 |
| TrulicityDulaglutide | 78 | $130,927 |
| FarxigaDapagliflozin Propanediol | 74 | $94,915 |
| MounjaroTirzepatide | 61 | $89,754 |
| TradjentaLinagliptin | 50 | $62,677 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 21 | $53,411 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 50 | $52,046 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $49,988 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $44,263 |
| Cinacalcet Hcl | 32 | $27,863 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 160 | $25,950 |
| Humalog Kwikpen U-100Insulin Lispro | 79 | $25,113 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $24,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $111 | $507,920330 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $106 | $235,765207 claims |
| Boehringer IngelheimJardiance, Tradjenta | $354 | $212,389170 claims |
| AstraZenecaFarxiga | $679 | $94,91574 claims |
| Sanofi-aventis U.S. LLCLantus, Soliqua 100-33 | $63 | $11,44835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Mesa
- Vidhyalakshmi KannanMesa$111K
- Gyan BrardMesa$12K
- Shahzad ShadmanyMesa$9K
- Roberta EscaleraMesa$5K
- Kevin YuenPhoenix$733K
- Muhammad SethiTucson$670K
- Amir HarariScottsdale$361K
- Joan BaileyPhoenix$316K
- Kristina BlohmScottsdale$220K
- Karen HerbstTucson$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.